|
|||||
|
|
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer |
|
| Authors: | Gong Chang Cheng Ziliang Yang Yaping Shen Jun Zhu Yingying Ling Li Lin Wanyi Yu Zhigang Li Zhihua Tan Weige Zheng Chushan Zheng Wenbo Zhong Jiajie Zhang Xiang Zeng Yunjie Liu Qiang Huang R. Stephanie Komorowski Andrzej L. Yang Eddy S. Bertucci François Ricci Francesco Orlandi Armando Franceschini Gianluca Takabe Kazuaki Klimberg Suzanne Ishii Naohiro Toss Angela Tan Mona P. Cherian Mathew A. Song Erwei |
| Affiliation: | 1.Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China ;2.Department of Radiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China ;3.Clinical Research Design Division, Clinical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China ;4.Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China ;5.Department of Breast Surgery, the Second Affiliated Hospital, Shandong University, Jinan, 250033, China ;6.Department of Breast Surgery, Key Laboratory of Breast Diseases, Third Hospital of Nanchang, Nanchang, 330009, China ;7.Department of Breast Surgery, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510120, China ;8.Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China ;9.Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, 55455, USA ;10.Department of Surgery, College of Medicine, University of Rzeszów, Rzeszów, 35-959, Poland ;11.Department of Radiation Oncology, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA ;12.Laboratoty of Predictive Oncology, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, INSERM UMR1068, CNRS UMR725, Marseille, France ;13.Department of Drug Development and Innovation(D3i), Institut Curie, Paris, 75005, France ;14.Comprehensive Cancer Center, UOC di Oncologia Medica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, 00168, Italy ;15.Multidisciplinary Breast Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, 00168, Italy ;16.Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA ;17.Department of Surgery, MD Anderson Cancer Center, Houston, TX, 77030, USA ;18.Department of Plastic and Reconstructive Surgery, International University of Health and Welfare Hospital, Nasushiobara City, Tochigi, 329-2763, Japan ;19.Department of Oncology and Hematology, University Hospital of Modena, Modena, 41124, Italy ;20.MammoCare: Breast Clinic and Surgery in Singapore, Singapore, 228510, Singapore ;21.The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, 43210, USA ; |
| Abstract: | Science China Life Sciences - Patients with hormone receptor (HR)-positive tumors breast cancer usually experience a relatively low pathological complete response (pCR) to neoadjuvant chemotherapy... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |